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Abstract
The 22q11.2 deletion syndrome (22q11.2DS) is a neurodevelopmental disorder associated with a number of volumetric brain
abnormalities. The syndrome is also associated with an increased risk for neuropsychiatric disorders including schizophrenia and
autism spectrum disorder. An earlier meta-analysis showed reduced grey and white matter volumes in individuals with
22q11.2DS. Since this analysis was conducted, the number of studies has increased markedly, permitting more precise estimates
of effects and more regions to be examined. Although 22q11.2DS is clinically heterogeneous, it is not known to what extent this
heterogeneity is mirrored in neuroanatomy. The aim of this study was thus to investigate differences in mean brain volume and
structural variability within regions, between 22q11.2DS and typically developing controls. We examined studies that reported
measures of brain volume using MRI in PubMed, Web of Science, Scopus and PsycINFO from inception to 1 May 2019. Data
were extracted from studies in order to calculate effect sizes representing case–control difference in mean volume, and in the
variability of volume (as measured using the log variability ratio (lnVR) and coefficient of variation ratio (CVR)). We found
significant overall decreases in mean volume in 22q11.2DS compared with control for: total brain (g=−0.96; p < 0.001); total
grey matter (g=−0.81, p < 0.001); and total white matter (g=−0.81; p < 0.001). There was also a significant overall reduction
of mean volume in 22q11.2DS subjects compared with controls in frontal lobe (g=−0.47; p < 0.001), temporal lobe (g=
−0.84; p < 0.001), parietal lobe (g=−0.73; p= 0.053), cerebellum (g=−1.25; p < 0.001) and hippocampus (g=−0.90; p <
0.001). Significantly increased variability in 22q11.2DS individuals compared with controls was found only for the hippocampus
(VR, 1.14; p= 0.036; CVR, 1.30; p < 0.001), and lateral ventricles (VR, 1.56; p= 0.004). The results support the notion that
structural abnormalities in 22q11.2DS and schizophrenia are convergent, and also to some degree with findings in autism
spectrum disorder. Finally, the increased variability seen in the hippocampus in 22q11.2DS may underlie some of the
heterogeneity observed in the neuropsychiatric phenotype.
Introduction
22q11.2 deletion syndrome (22q11.2DS), also known as
DiGeorge or Velo-Cardio-Facial syndrome, is a neurogenetic
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disorder with an estimated prevalence ranging between
1:3000 and 1:6000 [1] and is the most commonly occurring
microdeletion in humans [1–3]. About 90% of the cases arise
from de novo mutations, whilst about 10% are inherited in an
autosomal dominant pattern. The 22q11.2 locus is one of the
most complex regions in the genome due to the large clusters
of low copy repeats (LCR), which predict genomic instability
[4, 5]. Non allelic homologous recombination between LCRA
and LCRD, the two largest LCRs, leads to a 3Mb deletion
and accounts for 90% cases, whereas recombination of LCRA
and LCRB or LCRA and LCRC leads to 1.5 and 2Mb
deletions, respectively [4–6]. It has been suggested that
variability in the deletion size and breakpoint locations, as
well as characteristics of the intact chromosome are likely to
be playing an important role in the clinical phenotype of
individuals with 22q11.2DS [7]. The physical manifestations
have their onset in early childhood and include abnormalities
of the cardiac, endocrine and immune systems in addition to
facial deformities and cleft palate [1, 8]. Furthermore, anxiety
disorders are prevalent across the lifespan and by adolescence
mood disorders emerge [9]. In addition, neurodevelopmental
disorders such as autism spectrum disorder (ASD) have
estimated prevalence rates between 18 and 58% [9–12]. Over
the last 20 years, it has been well established that indi-
viduals with 22q11.2 deletion have greater than 25% risk
of developing psychosis [9], making this copy number
variant one of the strongest risk factors for the develop-
ment of psychosis [13, 14].
Given the neuropsychiatric sequelae of the syndrome,
there has been considerable interest in brain structure in
22q11.2DS. There have been two meta-analyses on struc-
tural neuroimaging studies in 22q11.2DS to date. The first
meta-analysis reported global volumetric reductions of total
grey and white matter, as well as reductions in frontal cortex
and hippocampal volume [15]. Authors further found that
the magnitude of the effect sizes increased from frontal
towards the occipital regions [15], supporting the theory
that brain structural abnormalities in 22q11.2DS may reflect
neurodevelopmental pathology along the rostrocaudate
gradient [16]. More recently Sun et al. conduced a large
multicentre study, examining cortical grey matter, and
showed overall decreased volume, driven by reduced sur-
face area, and increased cortical thickness, with the excep-
tion of the temporal pole [17].
As 22q11.2DS confers significant risk for both schizo-
phrenia and ASD, the question as to whether they share
similar structural abnormalities has been repeatedly asked
[10, 12, 18–25]. Moreover, in 22q11.2DS, the physical and
psychiatric consequences of the deletion are highly variable,
both in terms of nature and degree of symptomatology,
suggesting that multiple neurobiological pathways may
mediate the relationship between genes and phenotypic
expression [7]. Therefore, when examining the brain
structure, it is also important to consider the variability of
brain regions volumes. This enables the examination of
whether the clinical heterogeneity of the disorder is simi-
larly reflected at the level of neuroanatomy and whether the
evidence of differences in subgroups is a false positive
finding deriving from the selection of individuals from
extreme ends of distribution of similar variance to that of
healthy volunteers, but with shifted mean. Variability is a
relatively new concept, which was examined recently by a
meta-analysis in idiopathic schizophrenia [26]. Although
one might expect similar neuroanatomical variability to be
present in 22q11.2DS, this has not yet been tested.
Since the publication of an initial meta-analysis of
structural brain differences by Tan et al. [15], including
studies up to March 2008, the total number of structural
magnetic resonance studies in 22q11.2DS has almost dou-
bled, and to our knowledge, no previous study has exam-
ined variability of brain region volumes in 22q11.2DS. This
study therefore aimed to (1) perform an updated meta-
analysis of mean volume differences between individuals
with 22q11.2DS and typically developing controls; and (2)
examine differences in brain structural variability between
groups. We hypothesised that there would be volumetric
reductions in total white and grey matter, as well as in
cortical and subcortical regions including frontal, temporal,
parietal lobe and hippocampus, and further that neuroana-




A comprehensive search was conducted of PubMed, Web
of Science, Scopus and PsycINFO from inception to 1st
May 2019. Search terms used to identify the studies
included: 22q11.2 DS OR DiGeorge OR Velo-Cardio-
Facial syndrome OR Shprintzen syndrome OR CATCH22,
Conotruncal anomaly face syndrome; AND magnetic
resonance (MRI) OR volume OR SBM OR seed OR mor-
phology OR morphometry OR gray/grey OR cortical OR
anatomy OR structur* OR brain. In addition, we supple-
mented the search by manual and bibliographic cross
referencing, and by examining the previous meta-analysis
[15] to identify potentially missed studies (see Supple-
mentary Fig. 1 for flow chart).
Studies were initially included if they were (1) published
as a peer-reviewed article with original data and reported
measures of regional brain volumes in individuals with
22q11.2DS and typically developing controls; (2) had suf-
ficient data to extract mean and standard deviations for both
groups; and (3) were written in English. For papers with
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missing information, authors were contacted for raw data
and/or means and standard deviations.
In papers where samples overlapped, we only included
the study with the largest participant size. However, some
of the smaller studies included regions that were not cov-
ered in the larger paper and, if so, these duplicate samples
remained included for the missing regions, but weighted by
the smaller participant number. The search, screening and
data extraction was completed independently by three
separate researchers, MR, MG and CEB.
Measures reported by subgroups (e.g. male vs. female or
two control groups) were included as separate results. To
avoid overweighting, in cases where a control group was
used multiple times against different patient groups, the
number of participants recorded for that studies’ control
group was reduced accordingly, in line with standard
guidelines [27]. Where studies presented left and right
hemisphere volumes separately, these were combined to a
single measure, as previously described [28], using corre-
lation coefficients derived from an existing dataset (see
Supplementary Table 1).
Means and standard deviations of volumetric measures
for both patient and control groups were extracted. Brain
structures were included in the analysis if at least three
studies met the inclusion criteria. Further, we recorded
details of the potential moderating factors, such as sex
and IQ.
Outcome measures for mean differences
A meta-analysis of between-group differences in mean
volumes was conducted, indexed using Hedges g.
Outcome measures for variability
We measured the relative variability of brain regions in
patients compared with controls, by using the log variability
ratio (InVR): [26, 29]







2ðnp  1Þ 
1
2ðnc  1Þ ;
where σp and σc are unbiased estimates of population
standard deviations, Sp and Sc are reported samples standard
deviations, and np and nc are the sample sizes for patient and
control. However, as variance is positively correlated with
mean, some of the between-group difference in relative
variability might be partly driven by between-group
differences in the mean. This is in particular true for brain
structures with larger mean volume in patients, such as
lateral ventricles. We therefore also calculated the log
coefficient of variation ratio (lnCVR), which is a more
conservative test [26, 29]. The latter term, measures
variability differences after accounting for differences in
mean:







2ðnp  1Þ 
1
2ðnc  1Þ ;
where xp and xc are the reported means for patients and
controls.
Statistical analysis
As many of our studies reported volumes for multiple
structures of interest, we used a multivariate approach,
enabling an estimation of summary effect sizes across all
regions of interest, while reducing multicity concerns [30].
This approach estimates covariance among outcome mea-
sures, thereby improving estimation of summary effect size
relative to univariate analysis [31].
All analyses were conducted using the metafor package
in R (3.3.2) [32]. Separate multivariate random effect
models for Hedges’ g, lnVR and lnCVR were performed so
as to conduct meta-analysis of all regions concurrently [32].
We added random effects to the model for each region
within each study and region was added to the model as a
categorical moderator to derive summary effect size for
regions separately. Random effects models were then fitted
to data in all regions by means of restricted maximum
likelihood estimation for Hedges g, lnVR and lnCVR. A
Wald-type chi-square omnibus test was performed to assess
the significance of the model coefficients across regions.
For each significant omnibus test, we tested the effect
separately by region. Where VR (or CVR) was 1, equal
variability between patients and controls were found,
whereas >1 indicated greater variability in the patient group,
and <1 indicated lower variability in the patient group.
In addition, an omnibus test of effect of moderators was
used to examine the overall effect of region on mean values
and subsequently post hoc tests were applied to assess
differences between regions at pairwise level. In view of the
number of tests we conducted, we employed false discovery
rate adjustment of the probability threshold to the expected
proportion of type I error to 5% of rejected null hypotheses.
Meta-regression/sensitivity analysis
To examine the effects of moderating factors on mean dif-
ferences and variability, we employed a univariate mixed
effects meta-regression. We separately examined age, sex
and IQ as moderators for the mean volume differences and
variability. No correction for multiple comparisons was
applied when assessing effects at the level of the individual
region, as these meta-regression analyses were exploratory.
Eleven studies in the meta-analysis included individuals
with 22q11.2DS with psychiatric comorbidities (e.g. psy-
chosis, ASD, ADHD, anxiety and mood disorder) or on
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psychotropic medication. To test whether diagnosis had an
influence on our results, we repeated the analysis for mean
volume differences and variability only for individuals with
22q11.2DS without psychiatric comorbidities.
Publication bias and inconsistency for meta-analysis
of mean differences
Publication bias was assessed across all regions simulta-
neously by inspection of funnel plots of standard errors
against regional residuals and by a multivariate analogue of
Egger’s regression test [33]. Inconsistency between studies
was evaluated using the I2 statistic (with >50% con-
ventionally indicating moderate–high inconsistency and
<50% indicating low–moderate inconsistency [34]), an




A total of 24 studies, reporting data from 988 individuals
with 22q11.2DS and 873 controls were included (see
Table 1). Inter-rater reliability was assessed using Fleiss
Kappa test. The kappa was 0.9 for included studies and 0.94
for data extraction, reflecting excellent between rater relia-
bility. Sufficient studies were found to conduct analyses for
the following regions: total brain, total grey matter, total
white matter, cerebral spinal fluid, frontal, temporal and
parietal lobes, cerebellum, lateral ventricles, caudate
nucleus, amygdala and hippocampus. Mean (standard
deviation) age for individuals with 22q11.2DS was 14.4
(5.8) years and for controls 14.5 (6.6), and the male:female
percentage (%) was 50:50 in the 22q11.2DS group and
53:47 in the control group.
Mean differences
We found significant overall decreases in mean volume in
22q11.2DS compared with controls for: total brain (g=
−0.96; 95% CI, −1.26 to −0.65, p < 0.001); total grey
matter (g=−0.81; 95% CI, −0.97 to −0.65, p < 0.001);
and total white matter (g=−0.81; 95% CI, −0.98
to −0.64, p < 0.001), but no mean volume differences in
cerebral spinal fluid (g= 0.10; 95% CI, −0.21 to 0.42,
p= 0.519).
When examining brain regions, there was an overall
significant effect of group on mean volume (x2= 148.25,
p < 0.001). We also found significant overall decreases of
mean volume in 22q11.2DS compared with controls in
frontal lobe (g=−0.47; 95% CI, −0.68 to −0.25, p <
0.001), temporal lobe (g=−0.84; 95% CI, −1.19 to −0.48,
p < 0.001), parietal lobe (g=−0.73; 95% CI, −1.46 to
0.01, p= 0.053), cerebellum (g=−1.25; 95% CI, −1.56 to
−0.95, p < 0.001) and hippocampus (g=−0.90; 95% CI,
−1.10 to −0.70, p < 0.001). There were no significant mean
effects of group for lateral ventricles (g= 0.02; 95% CI,
−0.54 to 0.58, p= 0.949), caudate nucleus (g= 0.07; 95%
CI, −0.25 to 0.39, p= 0.680) or amygdala (g= 0.08; 95%
CI, −0.21 to 0.36, p= 0.605) (see Fig. 1 and Supplemen-
tary Table 2). Pairwise interregional comparisons adjusted
for multiple comparisons were also calculated (see Sup-
plementary Table 3 for further details).
Variability ratio
In the brain regions we examined, we found significantly
increased variability in 22q11.2DS individuals compared
with controls for the hippocampus (VR, 1.15; 95% CI,
1.01–1.31; p= 0.036) and lateral ventricles (VR, 1.56; 95%
CI, 1.15–2.13; p= 0.004). Variability was not significantly
different between groups for any other regions: frontal lobe
(VR, 1.00; 95% CI, 0.78–1.27; p= 0.972), temporal
lobe (VR, 1.13; 95% CI, 0.86–1.46; p= 0.379), parietal
lobe (VR, 1.01; 95% CI, 0.80–1.28; p= 0.919), cerebellum
(VR, 0.92; 95% CI, 0.75–1.13; p= 0.417), caudate
nucleus (VR, 1.13; 95% CI, 0.94–1.35; p= 0.196) or
amygdala (VR, 1.09; 95% CI, 0.94–1.27; p= 0.260) (see
Fig. 2 and Supplementary Table 2).
Coefficient of variation ratio
There was increased variability in 22q11.2DS compared
with controls remained significant when using CVR for the
hippocampus (CVR, 1.30; 95% CI, 1.14–1.47; p < 0.001).
However, this was not the case for the lateral ventricles
(CVR, 0.89; 95% CI, 0.71–1.11; p= 0.304). Nor did
variability, using coefficient ratio, become significant for
any of the remaining regions; frontal lobe (CVR, 1.05; 95%
CI, 0.83–1.33; p= 0. 655), temporal lobe (CVR, 1.25;
95% CI, 0. 97–1.61; p= 0.090), parietal lobe (CVR, 1.08;
95% CI, 0.88–1.32; p= 0.451), cerebellum (CVR, 1.09;
95% CI, 0.88–1.34; p= 0.432), caudate nucleus (CVR,
1.09; 95% CI, 0.92–1.29; p= 0.311) or amygdala
(CVR, 1.12; 95% CI, 0.96–1.30; p= 0.139) or (see Fig. 3
and Supplementary Table 2).
Meta-regression/sensitivity analysis
Age was not associated with regional mean volume differ-
ences (p > 0.05 for all regions). Interestingly, we found that
sex was associated with the magnitude of mean volume
differences in frontal lobe (z=−2.38, p= 0.017) and lat-
eral ventricles (z= 3.12, p= 0.013), with studies containing
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a greater proportion of females showing greater reductions
in brain volumes (see Supplementary Fig. 2). In addition,
IQ was associated with lateral ventricles mean volume.
Studies with greater differences in IQ between 22q11.2DS
and healthy controls showed larger increase of lateral ven-
tricle volume for the 22q11.2DS group (z= 3.12, p=
0.002) (see Supplementary Fig. 3).
However, there was no significant relationship between
variability of age or IQ with hippocampal variability (z=
0.02, p= 0.86; z= 0.118, p= 0.578, respectively) (see
Supplementary Fig. 4), nor with variability in lateral ven-
tricles (z= 0.028, p= 0.87; z=−0.068, p= 0.845,
respectively) (see Supplementary Fig. 5).
When we conducted the analysis, excluding individuals
with 22q11.2DS with psychiatric comorbidities and/or
psychotropic medication, results remained similar both for
mean volume differences and variability (see Supplemen-
tary Results).
Publication bias and inconsistency
Using a multivariate analogue of Egger’s test [33], we
found that funnel plot asymmetry was significant for
Hedges g (x2= 25.98, p= 0.011), but not for lnVR (x2=
0.48, p= 0.975), nor lnCVR (x2= 2.107, p= 0.716) (see
Supplementary Fig. 5).
Inconsistency (between-study heterogeneity), as mea-
sured by l2, depending on brain regions, ranged from 23.82
to 76.89 for Hedges g, 0.30 to 71.51 for lnVR and 1.98 to
69.18 for lnCVR (Figs. 1–3).
Discussion
Our first finding was a widespread volumetric reduction in
22q11.2DS compared with typically developing controls in
total brain, total grey and total white matter with large effect
sizes. Further, we identified regionally specific decreases in
the volume of frontal and temporal lobe, as well as in
subcortical regions such as hippocampus. Secondly, we
identified the hippocampus as a region of uniquely
increased variability in 22q11.2DS.
Brain volume reductions in 22q11.2 deletion
Reductions in grey and white matter volume in 22q11.2DS
compared with controls have been a consistent finding
across studies. More recently, grey matter differences have
been examined as its two independent components, cortical
thickness and surface area [19, 22, 25, 36], with a study by
the ENIGMA 22q11.2DS consortium analysing the largest
sample to date (n= 474) [17], and finding reduced cortical
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area, whereas increases were found in cortical thickness
[17]. Similarly, studies have observed white matter reduc-
tions in this population, which might indicate potential
impairments in myelination, which could contribute to
abnormalities in brain circuitry. For example, a recent large
multicentre diffusion tensor imaging study from the
ENIGMA 22q11.2DS working group found decreased
diffusivities, with smaller and undulated axons in
22q11.2DS compared with healthy controls [37]. As such,
the aberrant axonal differentiation and migration in
22q11.2DS may lead to the reduction in gyral complexity
in the syndrome, which could drive the regional decreases
in surface area [37]. Further, in the 22q11.2 locus, there are
genes related to axonal migration, shaping brain
Fig. 2 The variability ratio
(VR) was significantly
increased in the lateral
ventricles and hippocampus,
indicating greater variability
in their volumes for
individuals with 22q11.2DS.
There were no significant VR for
any other sub-regions. VR
Variability Ratio; CL
Confidence Interval; P indicates
statistical significance; I2
indicates inconsistency.
Fig. 3 The coefficient of
variability ratio (CVR) was
significantly increased in
hippocampus, indicating
greater variability in volume
for individuals with
22q11.2DS. There were no
significant CVR for any other
sub-regions. CVR Coefficient
Variability Ratio; CL
Confidence Interval; P indicates
statistical significance; I2
indicates inconsistency.
Fig. 1 Mean volumes of total
brain, total grey matter, total
white matter, frontal lobe,




There were no significant mean
differences between groups for
cerebral spinal fluid (CSF),
parietal lobe, lateral ventricles,
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morphology (i.e. PIK4CA and RTN4R) [38, 39] and when
the microdeletion occurs, this may contribute to the
observed white matter abnormalities [24, 40].
Our results extend the findings of the original meta-
analysis [15], by both including a larger sample, and studies
with more updated methodological approaches. In the pre-
sent study, we found reduction in cortical and subcortical
regions including frontal, temporal, parietal lobe, cere-
bellum and hippocampus. When we conducted the omnibus
test and pairwise comparisons, the effect size in the volume
of frontal lobe volume was smaller than that in the cere-
bellum. No significant differences were observed between
frontal and temporal lobe or temporal lobe and cerebellum.
This outcome is only partly in agreement with the rostro-
caudal gradient (frontal < temporal < cerebellum) that has
been shown in previous studies, which may be explained by
increased sample size, or differences in methodological
approaches e.g. use of multivariate vs. univariate analysis.
Nonetheless, the finding of frontal < cerebellum is con-
sistent with an aberrant developmental trajectory along the
anterior–posterior axis early in developmental years
[15, 16], potentially secondary to disruption of genes that
encode neurodevelopmental morphogens that are implicated
in the rostro-caudal axis [41].
Given the increased rates of neuropsychiatric disorders in
22q11.2DS, drawing parallels with studies examining
individuals at high clinical and genetic risk for developing
psychosis and/or ASD is crucial to enhance understand the
neurodevelopmental phenotype of this microdeletion. For
example, a meta-analysis in individuals at high risk of
developing psychosis found structural abnormalities in
similar regions to those found in this study, with reduced
volume of middle and superior temporal gyri, middle frontal
gyrus, hippocampus, parahippocampus and anterior cingu-
late cortex [42]. Comparably, studies at genetic high risk
groups for psychosis (including unaffected first degree
relatives and twins discordant for schizophrenia) have
shown volumetric decreases in frontal lobe [43–45], tem-
poral lobe [46], hippocampus [43, 44, 47], para-
hippocampus [43, 48, 49], as well as increases of lateral and
third ventricles [43, 47]. Further metanalytic evidence in
first episode psychosis has shown an inverse correlation
between grey matter volume in temporal lobe and severity
of psychotic symptoms [48]. It is worth noting that there
was a larger magnitude of the effect sizes of mean differ-
ences in our study compared with the ones previously
reported in genetic high-risk groups for psychosis [50] and
in schizophrenia [26]. In addition, the most recent meta-
analysis by the ENIGMA Schizophrenia working group
showed widespread cortical thinning with regional specifi-
city and decrease in surface area without specificity in
psychosis [51]. Frontal and temporal lobe were the brain
regions with the largest effect sizes for both measures, with
specificity only for cortical thickness, but not for surface
area [51].
Similarly, in 22q11.2DS, a longitudinal study following
up adolescents over a 3-year period found an inverse cor-
relation between volume in the prefrontal, temporal lobe
and cerebellum with severity of total prodromal psychotic
symptoms [52]. In this study, only decrease of grey matter
volume in temporal lobe was associated with increase of
positive prodromal psychotic symptoms [52]. Moreover,
when comparing individuals with 22q11.2DS with or
without schizophrenia, Chow et al. showed an association
of the disorder with reduction of superior temporal gyrus
[18]. Further, a recent large-scale study in 22q11.2DS found
increased cortical thickness, along with decreased surface
area in 22q11.2DS relative to control [17], which is in
contrast with the widespread cortical thinning that has been
found in idiopathic schizophrenia [51]. However, there was
significant convergence of affected brain regions between
22q11.2DS and idiopathic schizophrenia. Individuals with
22q11.2DS and psychosis showing cortical thinning in
fronto–temporal regions compared with the ones without
psychosis, with effect sizes similar to the ones observed in
idiopathic schizophrenia [17]. Combined, these findings
might suggest that in individuals with 22q11.2DS, frontal
and medial temporal lobe grey matter loss linked to cortical
thinning may serve as a vulnerability marker for psychosis
[53].
Likewise, in the ASD literature, several of the observed
regions in this study have been highlighted. For example,
there is evidence that frontal and temporal regions appear to
be more affected than parietal and occipital regions, sug-
gesting that the temporal sequence of typical early brain
development (i.e. back to front) is perturbed in ASD [54]. A
recent large-scale study from the ENIGMA-ASD working
group has shown decreased volume in striatum, amygdala
and hippocampus, enlarged lateral ventricles, increased
frontal thickness and decreased temporal thickness with
small to moderate effect sizes in ASDs relative to controls
[55]. Our results partially overlap with these findings, for
example, by showing reductions in hippocampus. Although
there have been few studies in 22q11.2DS individuals with
ASD, the findings to date have implicated volumetric dif-
ference in the amygdala [10, 12], decreased cortical thick-
ness in bilateral parahippocampus [10] and increased
cortical volume and surface area in right parieto–temporal
regions, and left posterior cingulate and dorsolateral pre-
frontal cortex [25]. However, in view of the limited number
of structural imaging studies investigating ASD on
22q11.2DS, any interpretations about convergence of
affected regions between these disorders should be made
cautiously.
In summary, decrease in grey matter volume in frontal
and medial temporal lobe associated with cortical thinning
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in 22q11.2DS may suggest increased vulnerability to psy-
chosis. It still remains unclear whether structural abnorm-
alities in 22q11.2DS may help us explain the increased risk
for ASD. This becomes more complicated given that idio-
pathic ASD and schizophrenia share some neuroanatomical
abnormalities, as well as the high rates of comorbidity of
these disorders in the 22q11.2DS population. Future long-
itudinal studies in 22q11.2DS are needed to disentangle the
degree that these disorders share neuroanatomical variation,
and to establish common or distinct genetic or molecular
mechanisms across disorders.
Variability
In the second part of our study, we demonstrated greater
volumetric variability in the group of 22q11.2DS compared
with the group of typically developing controls in hippo-
campus and lateral ventricles; with this remaining sig-
nificant for the hippocampus when controlling for mean
volume of the region.
There are several potential explanations for this finding.
For example, it is possible that variability differences may
reflect heterogeneous biological mechanisms in 22q11.2DS,
suggesting that brain regions are affected differently across
carriers. In support of this notion, a large-scale study on
22q11.2DS has found that deletion size impacts on brain
structure, in particular for cortical surface area [17]. The
increased variability in hippocampus and lateral ventricles
may imply that these brain areas are affected only in some
patients or to a varying extent across carriers. The hippo-
campus plays a key role in memory and cognition and
aberrant morphology has been shown in schizophrenia,
ASD and 22q11.2DS. Previous studies in mice models of
22q11.2DS have shown reduced neurogenesis [56] and
density of dendritic spines in hippocampus [57], suggesting
that these processes may lead to morphological alterations
observed in 22q11.2DS. Moreover, it has been suggested,
that in children with 22q11.2DS, the reduction in hippo-
campal volume might be due to greater variation in the
shape of the anterior hippocampus, and a greater inward
deformation [58]. In addition, it has been demonstrated that
hippocampus, particularly ventral hippocampus, can reg-
ulate dopamine function via involvement of glutamatergic
input to nucleus accumbens that leads to increase of
GABAergic activity to the ventral pallidum [59]. Further-
more, evidence from preclinical and clinical data has shown
that hyperactivity of hippocampus in schizophrenia can lead
to increased tonic dopamine firing and hyperdopaminergia
[60, 61]. More recently, a longitudinal study in 22q11.2DS
showed a volumetric decrease of hippocampus, with indi-
viduals with 22q11.2DS and psychotic symptoms present-
ing with a further reduction of volume during adolescence, a
crucial period for the emergence of psychosis [62]. All
subfields in hippocampus were similarly affected, except
CA2/3, which was interestingly decreased in 22q11.2DS
and psychosis, suggesting that this atrophy is associated
with the appearance of psychotic symptoms [62]. In view of
the above, it can be speculated that hippocampal abnorm-
alities in 22q11.2DS may be more common in those who
develop psychosis. Thus, variability in the neurobiology
affecting the hippocampus may contribute to the clinical
heterogeneity, and explain why not all individuals with
22q11.2DS develop psychosis, consistent with differing
neurodevelopmental trajectories underlying psychosis [63].
On the other hand, there seems to be less evidence to
support a link between variability in hippocampus
and ASD.
Notably, we observed unaltered variability in frontal,
temporal, parietal, amygdala, cerebellum and caudate
regions, which suggest that these are affected consistently
among patients. Brugger et al. reported greater volumetric
variability in individuals with first episode psychosis in
putamen, temporal lobe, thalamus and third ventricle,
unaltered variability in frontal lobe and caudate, and
reduced variability in anterior cingulate cortex, supporting
neurobiological heterogeneity in this disorder and high-
lighting the anterior cingulate cortex as a core component of
the biological processes across schizophrenia subtypes [26].
Our results suggest a level of convergence with the previous
variability meta-analysis, showing unaltered variability of
frontal lobe and caudate and increased variability in hip-
pocampus. However, when comparing the studies, it is
important to bear in mind, that individuals included in our
meta-analysis, were much younger and therefore, less likely
to have developed psychotic symptoms/psychosis. There-
fore, any interpretation should be made cautiously.
Another possible explanation is that the variability dif-
ferences we observe may be due to homogeneity of the
control groups, who are often unusually healthy, as the
presence of significant illness are often recruitment exclu-
sion criteria for controls, while individuals with 22q11.2DS
are at increased risk of numerous physical and mental
comorbidities [64]. This is, of course, an issue in general to
case–control research across medicine, however the concern
is more acute in relation to measures of variability (as
opposed to mean differences), as here, “the noise is the
signal”. It is worth noting that in the majority of the studies
we included in our analysis, IQ was higher in controls than
in individuals with 22q11.2DS. In the meta-regression we
conducted, we found that IQ had a significant effect on
mean volume differences in lateral ventricles, however,
there was no association between variability in hippo-
campus and/or lateral ventricles with variability in IQ. To
our knowledge, no study has previously examined the effect
of IQ on lateral ventricles volume in 22q11.2DS. Deboer
et al. previously investigated the relationship between
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hippocampal volume and IQ in 22q11.2DS [65]. Authors
showed that there was a strong association between hip-
pocampal volume and Verbal IQ, which is relatively pre-
served in this group. In contrast, no correlation was found
between hippocampal volume with Performance IQ [65].
Thus, the lack of association between hippocampal varia-
bility with variability in IQ in our study does not exclude
the possibility of relationship between hippocampal varia-
bility with specific cognitive functions. However, we were
unable to test this due to the small number of studies pro-
viding this information. Moreover, we found no association
between age variability and variability in either hippo-
campus or lateral ventricles, which may not be surprising
given that groups in the studies were matched for age.
Limitations and future directions
First, there was evidence for moderate-to-high incon-
sistency of effect size estimates for mean volume differ-
ences for some brain regions, with parietal lobe having the
highest inconsistency (i.e. I2= 72%). However, there were
only three studies for this region, thus a relatively large
effect size confidence interval for this measure. Although
the meta-regression indicated that age did not account for
the observed inconsistency, sex did significantly influence
our findings for mean volumetric differences in frontal lobe
and lateral ventricles. Studies with a greater proportion of
females had greater reduction in brain volume. In addition,
IQ was associated with the mean volumetric differences for
lateral ventricles, with studies with a greater difference in
IQ between the two groups showing larger lateral ventricle
volumes in the patient group. For the variability analysis,
inconsistency was found in frontal lobe and lateral ven-
tricles (i.e. I2= 74%, both for VR and CVR). However, the
random effects model was applied in our analysis, which
takes into account inconsistency.
In the sensitivity analysis, we demonstrated that diag-
nosis did not influence our results for either mean volume
differences or variability.
Second, our regression test showed asymmetry of the
funnel plot for mean volumetric differences, which may
represent a degree of publication bias. In contrast, we did
not find significant asymmetry for lnVR or lnCVR, which is
perhaps unsurprising as variability is rarely a primary out-
come in imaging studies.
Third, as the majority of the studies in our analysis
included young individuals and adolescents, it is not clear
whether we can extrapolate our results to the adult popu-
lation of 22q11.2DS. It is important to consider different
neurodevelopmental stages when comparing individuals
with 22q11.2DS, as rates of cortical development are not
linear across lifespan, and it is unclear at which exact stages
it might be disrupted in this population. Moreover, due to
insufficient number of studies to conduct a meta-analysis in
some brain regions that have been involved previously in
22q11.2DS, such as occipital lobe [66, 67], anterior cin-
gulate cortex [19, 68], insula [69], it would be crucial in the
future to expand this analysis in these regions when more
data are available, as well as in current regions (i.e. par-
ietal), where only a small number of studies was available.
Last, many of the studies included in this meta-analysis
examined large regions of interest and used techniques,
which do not compare regions on a voxel-wise basis. In
contrast, recent studies deploy the Freesurfer software
(http://surfer.nmr.mgh.harvard.edu/) which enables accurate
and robust registration and parcellation of cortical regions
[70]. Similarly, a vertex-based approach has recently being
employed in the analysis in an attempt to detect subtle and
spatially distributed differences across regions [25].
Currently, large-scale multicentre imaging studies are
being conducted, as part of the ENIGMA 22q11.2DS con-
sortium, using advanced approaches (e.g. FreeSurfer) for
the analysis of grey and white matter structures in this
microdeletion. Results to date have shown the size of the
22q11.2 deletion can influence brain structure [17]. In one
of these studies, reduction in cortical grey matter volume
was found, driven by reductions in surface area, whereas
cortical thickness was increased [17]. Further, the spatial
pattern of thicker cortex resembled that of surface area
reduction [17]. Similarly, there were large effects of the
22q11.2 deletion on white matter microstructure, such as
widespread reductions in mean, axial and radial diffusivities
in 22q11.2DS, especially in regions with major cortico-
cortical and cortico-thalamic fibres [37]. Authors proposed
that the pattern of abnormalities observed may reflect dis-
rupted neurogenesis of projection neurons in outer cortical
layers [37]. However, none of these studies have yet
investigated the neuroanatomical variability within regions.
Future studies should, where possible, examine this in more
detail, both in regards to grey and white matter, as well as
across regions in an attempt to detect more subtle and
spatially distributed differences.
Conclusions
In summary, we found that 22q11.2DS is associated with
both global and regional volumetric decrease in total brain,
total grey and white matter, frontal, temporal, parietal lobe,
cerebellum and hippocampus. Our meta-analysis further
suggests that there might be a convergence in neuroanato-
mical abnormalities between 22q11.2DS and what has
previously been found in schizophrenia and to some degree
in ASD. Finally, the increased variability in hippocampus in
22q11.2DS may explain some of the neuropsychiatric het-
erogeneity we observed in this genetic mutation and may be
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more likely associated with the emergence of psychosis.
Future large-scale structural imaging studies are required to
test the potential utility of the increased variability of hip-
pocampus for stratification or prognostic biomarker in
22q11.2DS.
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